News & Events about Rapt Therapeutics Inc.
RAPT Therapeutics, Inc. (NASDAQ:RAPT Get Rating) insider William Ho sold 5,000 shares of the stock in a transaction dated Wednesday, April 19th. The shares were sold at an average price of $18.88, for a total value of $94,400.00. Following the transaction, the insider now directly owns 20,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT PR Newswire NEW YORK, April 3, 2023 NEW YORK, April 3, 2023...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT PR Newswire NEW YORK, March 22, 2023 NEW YORK, March 22, 2023...
ATLANTA, March 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RAPT Therapeutics, Inc. (RAPT Therapeutics,or the Company) (NASDAQ: RAPT) complied with federal securities laws. On March 14, 2023, the Company disclosed that for its Phase 2b trial of RPT193 in atopic ...
Company maintains strong cash position of $249.1 millionSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies...